Kinoxis Therapeutics Pty Ltd is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic small molecule compounds for the treatment of substance use disorders and other neurological conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in several different animal models and is currently progressing through pre-clinical testing. Kinoxis was spun out of the University of Sydney in February 2018 through a $3.9m Series A investment round, led by university venture fund Uniseed. The compounds licensed are the result of a collaboration between the School of Chemistry and School of Psychology, through projects led by Professor Michael Kassiou, Professor Iain McGregor and Dr Michael Bowen. The primary target of the company is the brain oxytocin system, which is the focus of much interest because of its central role in the positive regulation of social behavior and its inhibitory effects on addictive behaviors. Substance use disorders, including the abuse of alcohol, nicotine, illicit and prescription drugs, represent a considerable treatment challenge for health care professionals. There are currently only a limited number of drugs approved for the treatment of substance use disorders.